195 related articles for article (PubMed ID: 12220960)
1. Biochemical and hematological side effects of clofazimine in leprosy patients.
Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
[TBL] [Abstract][Full Text] [Related]
2. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
[TBL] [Abstract][Full Text] [Related]
3. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
Queiroz RH; Souza AM; Melchior E; Gouveia EG; Carvalho D
Lepr Rev; 1997 Sep; 68(3):212-7. PubMed ID: 9364821
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
8. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
10. Minocycline is effective and cosmetically preferred to clofazimine by leprosy patients in New York.
Levis WR; Spencer TI; Ladizinski B
J Drugs Dermatol; 2010 Aug; 9(8):906. PubMed ID: 20684139
[No Abstract] [Full Text] [Related]
11. Multidrug therapy regimen for leprosy.
Firooz A
J Am Acad Dermatol; 2006 Dec; 55(6):1115; author reply 1115. PubMed ID: 17110233
[No Abstract] [Full Text] [Related]
12. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Lim JT; Tan T
Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
[TBL] [Abstract][Full Text] [Related]
14. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
15. [Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
Goulart IM; Arbex GL; Carneiro MH; Rodrigues MS; Gadia R
Rev Soc Bras Med Trop; 2002; 35(5):453-60. PubMed ID: 12621663
[TBL] [Abstract][Full Text] [Related]
16. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
[No Abstract] [Full Text] [Related]
17. [New WHO recommendations for the treatment of leprosy].
Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
[No Abstract] [Full Text] [Related]
18. [Immuno-allergic accidents with rifamipcin].
Flageul B; Wagner L; Cottenot F
Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
[TBL] [Abstract][Full Text] [Related]
19. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions.
Groenen G; Janssens L; Kayembe T; Nollet E; Coussens L; Pattyn SR
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):236-44. PubMed ID: 3722962
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
Andrade VL; Marques AB; da Cunha LH; Avelleira JR
Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):435-40. PubMed ID: 3655459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
